Working… Menu

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03326674
Recruitment Status : Active, not recruiting
First Posted : October 31, 2017
Last Update Posted : January 22, 2021
Information provided by (Responsible Party):
Odonate Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : August 24, 2020
Estimated Study Completion Date : March 2023